GeneDx Holdings Corp. reported second quarter 2026 financial results for the period ending June 30, 2026. Revenue increased 11% year-over-year to $114.4 million, driven by a 17% rise in exome and genome test revenue to $100.3 million and a 32% increase in volume to 30,785 tests. The company reported an adjusted net income of $0.4 million and reaffirmed its full year 2026 revenue guidance of $475 to $490 million. Concurrently, GeneDx amended its loan agreement with Blackstone to add a $50.0 million term loan facility, increasing the aggregate available principal to $150.0 million. An affiliate of Blackstone also agreed to purchase approximately $5.0 million of Class A common stock at $61.00 per share in a private placement. GeneDx operates in the genomic diagnostics industry, providing rare disease diagnosis and health insights through exome and genome testing.